Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613119 · ClinicalTrials.gov registry record
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
A clinical trial of Dementia and Frontotemporal Lobar Degeneration, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 108
- Enrollment target
- 1
- Study location
NCT00613119: Completed study of Dementia and Frontotemporal Lobar Degeneration, sponsored by National Institute of Mental Health (NIMH).
NCT00613119 is a study of Dementia and Frontotemporal Lobar Degeneration that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 108 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00613119, a study of Dementia and Frontotemporal Lobar Degeneration, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate the relationship between FTD and inflammation. Patients with FTD and healthy volunteers who are 35 years of age or older may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood and urine tests. Participants undergo the following procedures: * Whole body PET scan: PET uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is \[11C\]PBR28. Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer. Pictures are taken for 1 hour. This short scan is done to determine if \[11C\]PBR28 binds to the subject s receptors, since a number of people do not have binding. Subjects who have binding continue with brain PET and MRI scans, described below. * Brain PET imaging: Before starting the scan, a catheter is placed in a vein in the arm to inject the tracer,\<TAB\> and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. The subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. An 8-minute transmission scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed. * Blood and urine tests are done the day of and the day following each PET scan. * Magnetic resonance imaging (MRI):
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2008-01-31 |
| Est. Completion | 2017-07-13 |
What the finished NCT00613119 record still lists
NCT00613119 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 0 interventions.
NCT00613119 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00613119 about?
NCT00613119 is a clinical study titled "PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia". This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate...
What is the current status of trial NCT00613119?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2008-01-31. Estimated completion is 2017-07-13.
What conditions does trial NCT00613119 study?
This clinical trial studies the following conditions: Dementia, Frontotemporal Lobar Degeneration.
Who is sponsoring clinical trial NCT00613119?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00613119 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00613119's enrollment target sits among peer trials
108 115th of 199 higher than 85 of 199 other Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI